INTRODUCTION: Diabetes mellitus is associated with an increased risk of adverse clinical outcomes after percutaneous coronary intervention (PCI). The prognosis of patients with diabetes mellitus and chronic total occlusion (CTO) treated with PCI is poorly investigated. Current study evaluates outcome of successful PCI on CTO in patients with and without diabetes. METHODS: One hundred and sixty three patients treated with successful PCI on CTO between January 2009 and March 2011 were prospectively identified from the PCI registry at the Madani Heart Center, Tabriz, Iran. Patients were followed for 15±3 months, were evaluated for the occurrence of major adverse cardiac events (MACE) comprising death, acute myocardial infarction, and need for repeat revascularization. RESULTS: No differences were found in baseline clinical and procedural variables between patients with (n=34) and without diabetes (n=129), unless for hypertension (p=0.03). Hospitalization period after PCI in diabetics (3.26±0.61 days) and non-diabetics (2.86±0.52 days) was similar. In-hospital MACE occurred in 8 (23.5%) individuals of diabetics and 10 (7.8%) individuals of non-diabetics (p=0.02), among them revascularization was significantly higher in diabetics (20.6% vs. 7%, p=0.04). Follow-up events in diabetic and non-diabetic groups were 12 (35.3%) and 37 (28.5%), respectively (p was not significant). CONCLUSION: In patients undergoing successful PCI on CTO, diabetes is associated with higher in-hospital adverse events; however diabetes does not affect long term outcomes in these patients.
INTRODUCTION:Diabetes mellitus is associated with an increased risk of adverse clinical outcomes after percutaneous coronary intervention (PCI). The prognosis of patients with diabetes mellitus and chronic total occlusion (CTO) treated with PCI is poorly investigated. Current study evaluates outcome of successful PCI on CTO in patients with and without diabetes. METHODS: One hundred and sixty three patients treated with successful PCI on CTO between January 2009 and March 2011 were prospectively identified from the PCI registry at the Madani Heart Center, Tabriz, Iran. Patients were followed for 15±3 months, were evaluated for the occurrence of major adverse cardiac events (MACE) comprising death, acute myocardial infarction, and need for repeat revascularization. RESULTS: No differences were found in baseline clinical and procedural variables between patients with (n=34) and without diabetes (n=129), unless for hypertension (p=0.03). Hospitalization period after PCI in diabetics (3.26±0.61 days) and non-diabetics (2.86±0.52 days) was similar. In-hospital MACE occurred in 8 (23.5%) individuals of diabetics and 10 (7.8%) individuals of non-diabetics (p=0.02), among them revascularization was significantly higher in diabetics (20.6% vs. 7%, p=0.04). Follow-up events in diabetic and non-diabetic groups were 12 (35.3%) and 37 (28.5%), respectively (p was not significant). CONCLUSION: In patients undergoing successful PCI on CTO, diabetes is associated with higher in-hospital adverse events; however diabetes does not affect long term outcomes in these patients.
Entities:
Keywords:
Chronic Total Occlusion; Diabetes; Percutaneous Coronary Intervention
Authors: Gerald S Werner; Andreas Krack; Gero Schwarz; Dirk Prochnau; Stefan Betge; Hans R Figulla Journal: J Am Coll Cardiol Date: 2004-12-21 Impact factor: 24.094
Authors: Angela Hoye; Kengo Tanabe; Pedro A Lemos; Jiro Aoki; Francesco Saia; Chourmouzios Arampatzis; Muzaffer Degertekin; Sjoerd H Hofma; Georgios Sianos; Eugene McFadden; Willem J van der Giessen; Pieter C Smits; Pim J de Feyter; Ron T van Domburg; Patrick W Serruys Journal: J Am Coll Cardiol Date: 2004-06-02 Impact factor: 24.094
Authors: S Elezi; A Kastrati; J Pache; A Wehinger; M Hadamitzky; J Dirschinger; F J Neumann; A Schömig Journal: J Am Coll Cardiol Date: 1998-12 Impact factor: 24.094
Authors: A Abizaid; R Kornowski; G S Mintz; M K Hong; A S Abizaid; R Mehran; A D Pichard; K M Kent; L F Satler; H Wu; J J Popma; M B Leon Journal: J Am Coll Cardiol Date: 1998-09 Impact factor: 24.094
Authors: J R Martinez-Parachini; A Karatasakis; D Karmpaliotis; K Alaswad; F A Jaffer; R W Yeh; M Patel; J Bahadorani; A Doing; P-K Nguyen-Trong; B A Danek; J Karacsonyi; A Alame; B V Rangan; C A Thompson; S Banerjee; E S Brilakis Journal: Diabet Med Date: 2016-11-03 Impact factor: 4.359
Authors: Jan-Erik Guelker; Lars Bansemir; Rainer Ott; Thomas Rock; Rosemarie Guelker; Dong-In Shin; Heinrich Klues; Alexander Bufe Journal: J Tehran Heart Cent Date: 2019-04
Authors: Nousjka P A Vranken; Saman Rasoul; Jasper J P Luijkx; Tobias F S Pustjens; Sonja Postma; Evelien J Kolkman; Elvin Kedhi; Sodiqur Rifqi; Michael K Y Lee; Henning Ebelt; Béla Merkely; Monica Verdoia; Wojtek Wojakowski; Arnoud A W J van 't Hof; Harry Suryapranata; Giuseppe De Luca Journal: Diabetes Metab Res Rev Date: 2022-04-22 Impact factor: 8.128